Dr Reddy’s, Aurigene and Kainomyx link up on anti-malarials

Indian drug maker Dr Reddy’s Laboratories (BSE: 500124) and its subsidiary Aurigene Pharmaceutical Services have signed a non-binding, memorandum of understanding (MoU) with US start-up Kainomyx, for the development and commercialization of affordable anti-malarial drug in the USA, Europe, and in low and middle-income countries.

The MoU remains subject to signing of a definitive agreement. With this collaboration, the companies intend to drive a comprehensive research and development agenda to leverage their strengths and accelerate the program.

Under the MoU, Kainomyx has agreed to lead the technical strategy and associated aspects for drug discovery and clinical phases, Aurigene has agreed to focus on developing cost-effective and scalable drug chemistry, and, while the program evolves, Dr Reddy’s will bring in its regulatory and market access expertise.